Cargando…

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival

Detalles Bibliográficos
Autores principales:	Weber, Jeffrey S., Poretta, Tayla, Stwalley, Brian D., Sakkal, Leon A., Du, Ella X., Wang, Travis, Chen, Yan, Wang, Yan, Betts, Keith A., Shoushtari, Alexander N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025208/ https://www.ncbi.nlm.nih.gov/pubmed/36538061 http://dx.doi.org/10.1007/s00262-022-03351-w

Ejemplares similares

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
por: Freeman, Morganna, et al.
Publicado: (2019)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior
por: Beisel, Cassie, et al.
Publicado: (2022)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study
por: Chen, Zhiju, et al.
Publicado: (2020)

The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis
por: Lin, Zhuang-Bin, et al.
Publicado: (2020)

Nomogram to predict overall survival and disease-specific survival with appendiceal mucinous adenocarcinoma
por: Yan, Qian, et al.
Publicado: (2019)

Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
por: Luo, Rui, et al.
Publicado: (2023)

Esthesioneuroblastoma: Summary of Single-center Experiences with Focus on Adjuvant Therapy and Overall Survival
por: Alotaibi, Hammam A, et al.
Publicado: (2019)

Covariate balance-related propensity score weighting in estimating overall hazard ratio with distributed survival data
por: Huang, Chen, et al.
Publicado: (2023)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma
por: Shoushtari, A. N., et al.
Publicado: (2016)

Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience
por: Nizam, Aaron, et al.
Publicado: (2019)

Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A multiple centers retrospective cohort study with propensity score matching
por: Du, Shibin, et al.
Publicado: (2020)

A Nomogram To Predict The Overall Survival Of Breast Cancer Patients And Guide The Postoperative Adjuvant Chemotherapy In China
por: Wang, Xin, et al.
Publicado: (2019)

The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy
por: Li, Yueyi, et al.
Publicado: (2022)

Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores—— A retrospective, propensity score matching analysis
por: Chen, Feng-Lin, et al.
Publicado: (2022)

Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis
por: Liu, Wei-Ren, et al.
Publicado: (2020)

Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2 Lymphadenectomy
por: Yang, Qiong, et al.
Publicado: (2013)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma
por: Li, Yan, et al.
Publicado: (2018)

Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis
por: Chen, Yaw-Sen, et al.
Publicado: (2021)

Comparison of overall survival in patients with unresectable hepatic metastases with or without transarterial chemoembolization: A Propensity Score Matching Study
por: Wang, F. Y., et al.
Publicado: (2016)

The impact of previous cancer on overall survival of bladder cancer patients and the establishment of nomogram for overall survival prediction
por: Wang, Zhengquan, et al.
Publicado: (2020)

Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy
por: Jácome, Alexandre A. A., et al.
Publicado: (2012)

Postoperative Adjuvant Imatinib Therapy-Associated Nomogram to Predict Overall Survival of Gastrointestinal Stromal Tumor
por: Liu, Xuechao, et al.
Publicado: (2022)

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
por: Gogate, Anagha, et al.
Publicado: (2023)

Adjuvant chemotherapy is not a decisive factor in improving the overall survival of pulmonary sarcoma: A population-based study
por: Liang, Long, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

A study on comparison of overall survival and disease- free survival among gastric cancer patients treated with two adjuvant and neoadjuvant methods
por: Saadati, K, et al.
Publicado: (2015)

A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study
por: Corino, Valentina D. A., et al.
Publicado: (2021)

Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study
por: Chen, Jiahui, et al.
Publicado: (2020)

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
por: Nie, Run-Cong, et al.
Publicado: (2020)

Significance of examined lymph nodes number and metastatic lymph nodes ratio in overall survival and adjuvant treatment decision in resected laryngeal carcinoma
por: Zhu, Xiaoke, et al.
Publicado: (2020)

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
por: Swallow, Elyse, et al.
Publicado: (2018)

Changes in Body Composition during Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer
por: Chung, Eric, et al.
Publicado: (2019)

Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy
por: Feng, Long-Hai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_loovlmpvakj94vbtsm8p16i5il